Takeda Research Investment’s Graeme Martin On Corporate Venture Capital’s Role in Developing Next-Generation Biologics: An Interview With PharmAsia News(Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
Attend any industry conference these days, and a general theme arises that venture capital is not as readily available as it once was. A dearth of venture funding, particularly for early-stage projects, could impact long-term future development of emerging biotechnologies.
You may also be interested in...
At PharmAsia Summit, VCs Discuss Financing Innovation in Asia
SAN FRANCISCO - In spite of the generally gloomy forecasts for the venture industry, emerging markets in Asia reveal selective opportunities that could bring strong returns for VCs
At PharmAsia Summit, VCs Discuss Financing Innovation in Asia
SAN FRANCISCO - In spite of the generally gloomy forecasts for the venture industry, emerging markets in Asia reveal selective opportunities that could bring strong returns for VCs
Takeda's ARB Enters Phase III Trials In Japan As Company Moves To Acquire U.S. Biopharmaceutical Firm IDM
TOKYO - Takeda Pharmaceutical's angiotensin receptor blocker compound TAK-536 has entered Phase III clinical trials in Japan, just as the country's largest drug maker moves to complete its tender offer for the acquisition of U.S. biotech outfit IDM Pharma